ALMUDENA CASCAJERO DIAZ at Instituto de Salud Carlos III - Research Interests, Publications & Academic Profile

ALMUDENA CASCAJERO DIAZ

Técnico Superior de Actividades Técnicas y Profesionales

Instituto de Salud Carlos III

Spain

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do Korean students reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Virology

40%

Immunology

40%

Sars-cov-2

30%

Vaccine Development

30%

Covid-19

20%

Influenza Research

20%

Immunotherapy

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles8

Characterisation of <i>Legionella</i> Clinical Isolates in Spain from 2012 to 2022.

Article Link

Year:

2024

Fulminant septic shock due to community-acquired pneumonia caused by Legionella pneumophila SG1 Olda OLDA ST1. Case report

Article Link

Year:

2024

Longer intervals between SARS‐CoV‐2 infection and mRNA‐1273 doses improve the neutralization of different variants of concern

Article Link

Year:

2023

Treatment with integrase inhibitors alters SARS‐CoV‐2 neutralization levels measured with HIV‐based pseudotypes in people living with HIV

Article Link

Year:

2023

Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study

Article Link

Year:

2022

Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study

Article Link

Year:

2022

Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19

Article Link

Year:

2022

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Article Link

Year:

2021

Collaborators6

Fernando González-Camacho

Instituto de Salud Carlos III

SPAIN

Antonio Portolés-Pérez

Profesor Titular Vinculado

Universidad Complutense de Madrid Facultad de Medicina

SPAIN

Alberto M. Borobia

SPAIN

Miguel Ángel García Garrido

Profesor. Coordinador de Prácticas Clínicas

Universidad Alfonso X el Sabio

SPAIN

Oleguer Parés-Badell

Assistant professor

University of Barcelona

SPAIN

Francisco Díez-Fuertes

Instituto de Salud Carlos III

SPAIN

How do Korean students reach out?

Meet Kite AI